YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer. (PubMed, Pharmaceuticals (Basel)) - Nov 27, 2025 - "YM155 (Sepantronium bromide) suppresses survivin expression and has demonstrated antitumor activity in preclinical models. The integration of clinical and functional data provides translational support for combining the survivin inhibitor YM155 with platinum-based therapy. These results warrant further validation in larger patient cohorts and in vivo models."
Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
Albert Font; Clara Alcon; Himisha Beltran; Joan Montero; Júlia Francisco-Rodon; Luís Palomero; Maria Fernández-Saorin; Mariona Figols; Martin K Bakht; Vicenç Ruiz de Porras; Vincenza Conteduca
|